Les nouvelles stratégies thérapeutiques au cours de la sclérose en plaques

Kurtzke, 1983, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 33, 1444, 10.1212/WNL.33.11.1444 Beck, 1993, The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple scIerosis.The Optic Neuritis Study Group, New Engl J Med, 329, 1764, 10.1056/NEJM199312093292403 Barnes, 1997, Randomised trial of oral and intravenous methylpredni- solone in acute relapses of multiple sclerosis, Lancet, 349, 902, 10.1016/S0140-6736(96)06453-7 Palace, 1997, New treatments and Azathioprine in multiple sclerosis, Lancet, 350, 261, 10.1016/S0140-6736(97)24030-4 Yudkin, 1991, Overview of azathioprine in treatment of multiple sclerosis, Lancet, 338, 1050, 10.1016/0140-6736(91)91909-E Confavreux, 1996, Risk of cancer from azathioprine therapy in multiple sclerosis: a cased-control study, Neurology, 46, 1607, 10.1212/WNL.46.6.1607 Weiner, 1993, Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group, Neurology, 43, 910, 10.1212/WNL.43.5.910 Goodkin, 1995, Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis, Ann Neurol, 37, 30, 10.1002/ana.410370108 1993, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, 655, 10.1212/WNL.43.4.655 1995, Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial, Neurology, 45, 1277, 10.1212/WNL.45.7.1277 Jacobs, 1996, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research group (MSCRG), Ann Neurol, 39, 285, 10.1002/ana.410390304 Rudick, 1997, Impact of interferon beta-1a on neurologie disability in relapsing multiple sclerosis, Neurology, 49, 358, 10.1212/WNL.49.2.358 Edan, 1997, Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria, J Neurol Neurosurg Psychiatry, 62, 112, 10.1136/jnnp.62.2.112 Millefiorini, 1997, Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome, J Neurol, 244, 153, 10.1007/s004150050066 Johnson, 1998, Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability, Neurology, 50, 701, 10.1212/WNL.50.3.701 Johnson, 1995, Copolymer reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, 45, 1268, 10.1212/WNL.45.7.1268 Fazekas, 1997, Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis, Lancet, 349, 589, 10.1016/S0140-6736(96)09377-4 Achiron, 1998, Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses, Neurology, 50, 398, 10.1212/WNL.50.2.398 Sorensen, 1998, Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis, Neurology, 50, 1273, 10.1212/WNL.50.5.1273